DaVita Clinical Research® (DCR®), a provider of clinical research and diagnostic laboratory services, demonstrated its scientific leadership in 2010 by opening its Central Laboratory, expanding its Health Economics leadership, and participating and presenting in a multitude of posters and abstracts at top renal industry meetings.

DCR led the industry in the number of renal patients enrolled in clinical trials, totaling 2,579 active patients. The company’s unsurpassed knowledge, skill and experience relating to kidney disease and scientific leadership is comprised of some of the world’s top nephrologists with more than 80 years of experience in renal research.

“We are pleased and very fortunate for the direction 2010 has led DCR,” stated DCR President Chris Rucker. “Our organization’s devotion to this industry is what helps us excel, and we are eager to continue with our efforts throughout 2011.”

DCR’s Central Laboratory, which opened in September 2010, features the latest in analytical methodology and technology. Investments in both equipment and its over 47,000-square-foot facility allow for generating a daily test volume of approximately 144,000 tests on 60,000 samples per day. With sincere dedication to conducting each client project on time, DCR holds an impressive rate of delivery at 99.8 percent. Having developed the latest milestone at the Central Laboratory – green packaging for samples – DCR combines its high delivery rate with a cost-effective and environmentally friendly method of shipping.

The DaVita® network, including DaVita, Inc., DCR and its renal-focused counterparts and partners were selected to represent a total of 56 posters and deliver five oral presentations at the American Society of Nephrology Annual Meeting and Scientific Exposition (ASN). DCR also had a strong presence at the Annual Dialysis Conference (ADC), delivering 20 presentations to an international group of practitioners and researchers. These numbers represent a notable presence by DaVita and the company’s related entities at both ASN and ADC, representing impactful research with great depth and thought leadership. Along with the company’s impressive number of abstracts and presentations, DCR had 23 articles published in peer-reviewed journals.

About DaVita Clinical Research
Davita Clinical Research® (DCR®) is committed to advancing the knowledge and practice of kidney care. DCR brings extensive knowledge, skill, and expertise to pharmaceutical research, enabling the success of their clients’ clinical trials. Their clinical expertise ranges from designing the study to preparing and submitting the final report. DCR’s Early Clinical Research unit (Phase I-IIa) and Clinical Development network of physicians and investigative sites is focused on providing world-class clinical research in both complex/specialty populations and therapeutic areas as well as CKD and ESRD populations needed to meet clinical goals. To learn more about DCR, visit www.davitaclinicalresearch.com.

About DaVita Inc.
DaVita Inc., a Fortune 500® company, is a leading provider of kidney care in the United States, delivering dialysis services and education to patients with chronic kidney failure and end stage renal disease. As of December 31, 2010, DaVita operated or provided administrative services at 1,612 dialysis facilities, serving approximately 125,000 patients. DaVita develops, participates in and donates to numerous programs dedicated to transforming communities and creating positive, sustainable change for children, families and our environment. The company’s leadership development initiatives and corporate social responsibility efforts have been recognized by Fortune, Modern Healthcare, Newsweek and WorldBlu, among others. For more information, please visit www.davita.com.